Novel phenotypic outcomes identified for a public collection of approved drugs from a publicly accessible panel of assays

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Lee, Jonathan A ^a   Shinn, Paul ^b   Jaken, Susan ^a   Oliver, Sarah ^a   Willard, Francis S ^a   Heidler, Steven ^a   Peery, Robert B ^a   Oler, Jennifer ^a   Chu, Shaoyou ^a   Southall, Noel ^b   Dexheimer, Thomas S ^b   Smallwood, Jeffrey ^a   Huang, Ruili ^b   Guha, Rajarshi ^b   Jadhav, Ajit ^b   Cox, Karen ^a   Austin, Christopher P ^b   Simeonov, Anton ^b   Sittampalam, G Sitta ^b   Husain, Saba ^a   Franklin, Natalie ^a   Wild, David J ^c   Yang, Jeremy J ^c   Sutherland, Jeffrey J ^a   Thomas, Craig J ^b   more..

^a ELI LILLY AND COMPANY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Indiana University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AXITINIB; BUTRIPTYLINE; DASATINIB; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIQUIDONE; GLUCAGON LIKE PEPTIDE 1; K RAS PROTEIN; MEBEVERINE; METITEPINE; PAZOPANIB; PROPAFENONE; REPAGLINIDE; ROTENONE; SORAFENIB; WNT PROTEIN; MOLECULAR LIBRARY;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG APPROVAL; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG RESPONSE; GENE MUTATION; HUMAN; HUMAN CELL; INSULIN RELEASE; INTRACELLULAR SIGNALING; MEDICAL LITERATURE; MOLECULAR WEIGHT; ONCOGENE K RAS; PHENOTYPE; PHENOTYPIC VARIATION; WNT SIGNALING PATHWAY; DRUG REPOSITIONING; HIGH THROUGHPUT SCREENING; IC50; MOLECULAR LIBRARY; PHARMACOLOGY; PRECLINICAL STUDY; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; DRUG REPOSITIONING; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; PHENOTYPE; SMALL MOLECULE LIBRARIES;

EID: 84941354419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130796     Document Type: Article

References (75)

1. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011; 10: 507-19. doi: 10.1038/nrd3480 PMID: 21701501
2. Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013; 154: 1151-61. doi: 10.1016/j.cell.2013.08.003 PMID: 23993102
3. Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2014; 111: 2349-54. doi: 10.1073/pnas.1311846111 PMID: 24469833
4. Swinney DC. The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines. Journal of biomolecular screening. 2013; 18: 1186-92. doi: 10.1177/1087057113501199 PMID: 23983234
5. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3: 673-83. doi: 10.1038/nrd1468 PMID: 15286734
6. Dandapani S, Rosse G, Southall N, Salvino JM, Thomas CJ. Selecting, Acquiring, and Using Small Molecule Libraries for High-Throughput Screening. Current Protocols in Chemical Biology: John Wiley & Sons, Inc.; 2009.
7. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011; 3: 80ps16. doi: 10.1126/scitranslmed.3001862 PMID: 21525397
8. Shen M, Zhang Y, Saba N, Austin CP, Wiestner A, Auld DS. Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. PLoS One. 2013; 8: e75252. doi: 10. 1371/journal.pone.0075252 PMID: 24073257
9. Yuan J, Cheng KC, Johnson RL, Huang R, Pattaradilokrat S, Liu A, et al. Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science. 2011; 333: 724-9. doi: 10.1126/science.1205216 PMID: 21817045
10. Lee JA, Chu S, Willard FS, Cox KL, Sells Galvin RJ, Peery RB, et al. Open innovation for phenotypic drug discovery: The PD2 assay panel. Journal of biomolecular screening. 2011; 16: 588-602. doi: 10. 1177/1087057111405379 PMID: 21521801
11. Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Journal of biomolecular screening. 1999; 4: 67-73. PMID: 10838414
12. Rindi G, Grant SG, Yiangou Y, Ghatei MA, Bloom SR, Bautch VL, et al. Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice. Heterogeneity of hormone expression. The American journal of pathology. 1990; 136: 1349-63. PMID: 2162628
13. Lee T, Schwandner R, Swaminath G, Weiszmann J, Cardozo M, Greenberg J, et al. Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Molecular pharmacology. 2008; 74: 1599-609. doi: 10.1124/mol.108.049536 PMID: 18818303
14. Sutherland JJ, Gao C, Cahya S, Vieth M. What general conclusions can we draw from kinase profiling data sets? Biochim Biophys Acta. 2013; 1834: 1425-33. doi: 10.1016/j.bbapap.2012.12.023 PMID: 23333421
15. Alvim-Gaston M, Grese T, Mahoui A, Palkowitz AD, Pineiro-Nunez M, Watson I. Open Innovation Drug Discovery (OIDD): a potential path to novel therapeutic chemical space. Current topics in medicinal chemistry. 2014; 14: 294-303. PMID: 24283973
16. Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S, et al. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. The Journal of pharmacology and experimental therapeutics. 2000; 293: 444-52. PMID: 10773014
17. Chadwick W, Wilson G, van de Venter M, OelofsenW, Roux S. Shifts in metabolic parameters surrounding glucose homoeostasis resulting from tricyclic antidepressant therapy: implications of insulin resistance? J Pharm Pharmacol. 2007; 59: 95-103. doi: 10.1211/jpp.59.1.0013 PMID: 17227626
18. Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry. 2006; 67: 1856-61. PMID: 17194262
19. Wu W, Shang J, Feng Y, Thompson CM, Horwitz S, Thompson JR, et al. Identification of glucosedependant insulin secretion targets in pancreatic beta cells by combining defined-mechanism compound library screening and siRNA gene silencing. Journal of biomolecular screening. 2008; 13: 128-34. doi: 10.1177/1087057107313763 PMID: 18216393
20. Iismaa TP, Kerr EA, Wilson JR, Carpenter L, Sims N, Biden TJ. Quantitative and functional characterization of muscarinic receptor subtypes in insulin-secreting cell lines and rat pancreatic islets. Diabetes. 2000; 49: 392-8. PMID: 10868960
21. Herbst M, Sasse P, Greger R, Yu H, Hescheler J, Ullrich S. Membrane potential dependent modulations of calcium oscillations in insulin-secreting INS-1 cells. Cell calcium. 2002; 31: 115-26. doi: 10. 1054/ceca.2001.0266 PMID: 12027385
22. Lowes DJ, Guiguemde WA, Connelly MC, Zhu F, Sigal MS, Clark JA, et al. Optimization of propafenone analogues as antimalarial leads. Journal of medicinal chemistry. 2011; 54: 7477-85. doi: 10.1021/ jm2005546 PMID: 21955244
23. Volvert ML, Seyen S, Piette M, Evrard B, Gangolf M, Plumier JC, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC pharmacology. 2008; 8: 10. doi: 10.1186/1471-2210- 8-10 PMID: 18549472
24. Ganesan L, Margolles-Clark E, Song Y, Buchwald P. The food colorant erythrosine is a promiscuous protein-protein interaction inhibitor. Biochemical pharmacology. 2011; 81: 810-8. doi: 10.1016/j.bcp. 2010.12.020 PMID: 21219880
25. Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, et al. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene. 2011; 30: 561-74. doi: 10.1038/onc.2010.430 PMID: 20956938
26. Garcia-Gomez A, Ocio EM, Crusoe E, Santamaria C, Hernandez-Campo P, Blanco JF, et al. Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One. 2012; 7: e34914. doi: 10. 1371/journal.pone.0034914 PMID: 22539950
27. Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R, et al. ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer cell. 2006; 9: 33-44. doi: 10.1016/j.ccr.2005.12.021 PMID: 16413470
28. Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res. 2012; 72: 1547-56. doi: 10.1158/0008-5472.CAN-11-3222 PMID: 22318865
29. Arlt A, Bauer I, Schafmayer C, Tepel J, Muerkoster SS, Brosch M, et al. Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene. 2009; 28: 3983-96. doi: 10.1038/onc.2009.264 PMID: 19734940
30. Lee J, Lee I, Han B, Park JO, Jang J, Park C, et al. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst. 2011; 103: 674-88. doi: 10.1093/ jnci/djr070 PMID: 21398618
31. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Cossetti C, et al. Reactive astrocytes and Wnt/ beta-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis. 2011; 41: 508-27. doi: 10.1016/j.nbd.2010.10.023 PMID: 21056667
32. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011; 286: 44326-35. doi: 10.1074/jbc.M111.283481 PMID: 22030390
33. Funato Y, Michiue T, Asashima M, Miki H. The thioredoxin-related redox-regulating protein nucleoredoxin inhibits Wnt-beta-catenin signalling through dishevelled. Nat Cell Biol. 2006; 8: 501-8. doi: 10. 1038/ncb1405 PMID: 16604061
34. Hoogeboom D, Burgering BM. Should I stay or should I go: beta-catenin decides under stress. Biochim Biophys Acta. 2009; 1796: 63-74. doi: 10.1016/j.bbcan.2009.02.002 PMID: 19268509
35. Murillo G, Peng X, Torres KE, Mehta RG. Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev Res (Phila). 2009; 2: 942-50. doi: 10.1158/1940-6207.CAPR-08-0232
36. Yoon JC, Ng A, Kim BH, Bianco A, Xavier RJ, Elledge SJ. Wnt signaling regulates mitochondrial physiology and insulin sensitivity. Genes Dev. 2010; 24: 1507-18. doi: 10.1101/gad.1924910 PMID: 20634317
37. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem. 2007; 282: 27298-305. doi: 10.1074/jbc.M702811200 PMID: 17623658
38. Kim KC, Friso S, Choi SW. DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging. J Nutr Biochem. 2009; 20: 917-26. doi: 10.1016/j.jnutbio.2009.06.008 PMID: 19733471
39. Crott JW, Liu Z, Keyes MK, Choi SW, Jang H, Moyer MP, et al. Moderate folate depletion modulates the expression of selected genes involved in cell cycle, intracellular signaling and folate uptake in human colonic epithelial cell lines. J Nutr Biochem. 2008; 19: 328-35. doi: 10.1016/j.jnutbio.2007.05.003 PMID: 17681772
40. Gray JD, Nakouzi G, Slowinska-Castaldo B, Dazard JE, Rao JS, Nadeau JH, et al. Functional interactions between the LRP6 WNT co-receptor and folate supplementation. Hum Mol Genet. 2010; 19: 4560-72. doi: 10.1093/hmg/ddq384 PMID: 20843827
41. Mayer-Kuckuk P, Banerjee D, Malhotra S, Doubrovin M, Iwamoto M, Akhurst T, et al. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression. Proc Natl Acad Sci U S A. 2002; 99: 3400-5. doi: 10.1073/pnas.062036899 PMID: 11891321
42. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. Adv Nutr. 2012; 3: 21-38. doi: 10.3945/an.111.000992 PMID: 22332098
43. Han M, Serrano MC, Lastra-Vicente R, Brinez P, Acharya G, Huhta JC, et al. Folate rescues lithium-, homocysteine- and Wnt3A-induced vertebrate cardiac anomalies. Dis Model Mech. 2009; 2: 467-78. doi: 10.1242/dmm.001438 PMID: 19638421
44. Klinghoffer RA, Frazier J, Annis J, Berndt JD, Roberts BS, Arthur WT, et al. A lentivirus-mediated genetic screen identifies dihydrofolate reductase (DHFR) as a modulator of beta-catenin/GSK3 signaling. PLoS One. 2009; 4: e6892. doi: 10.1371/journal.pone.0006892 PMID: 19727391
45. Zhao S, Nishimura T, Chen Y, Azeloglu EU, Gottesman O, Giannarelli C, et al. Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med. 2013; 5: 206ra140. doi: 10.1126/ scitranslmed.3006548 PMID: 24107779
46. Kim SY, Schneeweiss S, Liu J, Solomon DH. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res. 2012; 27: 789-96. doi: 10.1002/jbmr.1489 PMID: 22162140
47. Urano W, Furuya T, Inoue E, Taniguchi A, Urano T, Kotake S, et al. Associations between methotrexate treatment and methylenetetrahydrofolate reductase gene polymorphisms with incident fractures in Japanese female rheumatoid arthritis patients. J Bone Miner Metab. 2009; 27: 574-83. doi: 10.1007/ s00774-009-0073-7 PMID: 19333678
48. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86: 353-64. PMID: 8756718
49. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70. PMID: 10647931
50. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74. doi: 10. 1016/j.cell.2011.02.013 PMID: 21376230
51. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008; 358: 2039-49. doi: 10.1056/NEJMra0706596 PMID: 18463380
52. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8: 579-91. doi: 10.1038/nrc2403 PMID: 18596824
53. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8: 592-603. doi: 10.1038/nrc2442 PMID: 18650835
54. Giuliano S, Pages G. Mechanisms of resistance to anti-angiogenesis therapies. Biochimie. 2013; 95: 1110-9. doi: 10.1016/j.biochi.2013.03.002 PMID: 23507428
55. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer. 2010; 1: 12-25. doi: 10. 1177/1947601909356574 PMID: 21779425
56. 184th meeting of the American Chemical Society, 1982, MEDI 49.
57. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46: 3-26. PMID: 11259830
58. Katocs AS Jr., Schaffer SA. Antiatherogenic activity of cetaben sodium, sodium p-(hexadecylamino) benzoate, in the aortae of hypercholesteremic rabbits subjected to aortic endothelial cell desquamation. Artery. 1982; 11: 192-206. PMID: 6985202
59. Albright JD, Schaffer SA, Shepherd RG. Cetaben sodium, an antiatherosclerotic agent. J Pharm Sci. 1979; 68: 936-7. PMID: 313437
60. Hollander W, Prusty S, Nagraj S, Kirkpatrick B, Paddock J, Colombo M. Comparative effects of cetaben (PHB) and dichlormethylene diphosphonate (Cl2MDP) on the development of atherosclerosis in the cynomolgus monkey. Atherosclerosis. 1978; 31: 307-25. PMID: 152632
61. Schulz MM, Reisen F, Zgraggen S, Fischer S, Yuen D, Kang GJ, et al. Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis. Proc Natl Acad Sci U S A. 2012; 109: E2665-74. doi: 10.1073/pnas.1206036109 PMID: 22949700
62. Albright JD, DeVries VG, Du MT, Largis EE, Miner TG, Reich MF, et al. Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben. Journal of medicinal chemistry. 1983; 26: 1393-411. PMID: 6604817
63. Albright JD, DeVries VG, Largis EE, Miner TG, Reich MF, Schaffer SA, et al. Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben. Journal of medicinal chemistry. 1983; 26: 1378-93. PMID: 6604816
64. Kovacs WJ, Schrader M, Walter I, Stangl H. The hypolipidemic compound cetaben induces changes in Golgi morphology and vesicle movement. Histochem Cell Biol. 2004; 122: 95-109. doi: 10.1007/ s00418-004-0689-6 PMID: 15322860
65. Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. Journal of medicinal chemistry. 2012; 55: 4527-38. doi: 10.1021/ jm201649s PMID: 22409666
66. Bostrom J, Brickmann K, Johannesson P, Knerr LD, Petersson A, Schnecke V, et al., inventorsBISAMLDE DERIVATIVES AND USE THEREOF AS FATTY ACID SYNTHASE INHIBITORS2008.
67. Butlin R, Caulkett PWR, Newxombe NJ, O'Donnell CJ, Wood JM, inventorsPIPERIDINE DERIVATIVES FOR THE TREATMENT OF OBESITY2008.
68. Butlin RJ, Caulkett PWR, Johannesson P, Knerr LD, Leach A, Newxombe NJ, et al., inventorsSULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS 2008.
69. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97: 3450-4. doi: 10.1073/pnas.050582897 PMID: 10716717
70. Lookene A, Skottova N, Olivecrona G. Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat). European journal of biochemistry / FEBS. 1994; 222: 395-403. PMID: 8020477
71. Browne CD, Hindmarsh EJ, Smith JW. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J. 2006; 20: 2027-35. doi: 10.1096/fj.05-5404com PMID: 17012255
72. Seguin F, Carvalho MA, Bastos DC, Agostini M, Zecchin KG, Alvarez-Flores MP, et al. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas. Br J Cancer. 2012; 107: 977-87. doi: 10.1038/bjc.2012.355 PMID: 22892389
73. Sounni NE, Cimino J, Blacher S, Primac I, Truong A, Mazzucchelli G, et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell metabolism. 2014; 20: 280-94. doi: 10.1016/j.cmet.2014.05.022 PMID: 25017943
74. Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 2009; 100: 1369-72. doi: 10.1038/sj.bjc.6605007 PMID: 19352381
75. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007; 7: 763-77. doi: 10.1038/nrc2222 PMID: 17882277